ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders –– Topline Data Expected Mid-Year 2025 –MELBOURNE, Australia and ...

Alterity Therapeutics (ASX:ATH, NASDAQ:ATHE) has announced the completion of its last patient visit in the ATH434-202 ...

High sugar-sweetened beverage (SSB) intake is associated with an increased risk for oral cavity cancer (OCC) in women, ...

Existing research indicates that the accuracy of a Parkinson's disease diagnosis hovers between 55% and 78% in the first five years of assessment. That's partly because Parkinson's sibling movement ...

University of Florida researchers have led a multicenter study demonstrating that Automated Imaging Differentiation for ...

Across two cohorts, the Automated Imaging Differentiation for Parkinsonism (AIDP) machine learning model distinguished ...

This new cryo-EM structure represents a remarkable advance in our understanding of how human PINK1 is stabilized” said Miratul Muqit of the University of Dundee (comment below). “Komander and his team ...